BioMarker Strategies Announces that Both of Its Core Diagnostics Technologies for Solid Tumor Cancers Are Now Covered by New Patents Granted in Canada

March 28, 2018 |

5 min read

“Improved Methods and Devices for Cellular Analysis” (CA2703631) covers the SnapPath® Cancer Diagnostics System technology “Compositions and Methods for Prediction of Drug Sensitivity, Resistance, and Disease Progression” (CA2795362) covers PathMAP® Functional Signaling Profile technology

ROCKVILLE, Md.--(BUSINESS WIRE)-- BioMarker Strategies LLC today announced that the Canadian Patent Office has granted new patents covering its SnapPath® Cancer Diagnostics System technology and its PathMAP® Functional Signaling Profile technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180328005229/en/

The SnapPath® Cancer Diagnostics System is the only diagnostics system that can generate purified populations of live solid tumor cells from live, unfixed samples in an automated and standardized manner. SnapPath preserves the molecular integrity of these living cells for exposure outside the human body to targeted therapies. This enables the generation of PathMap® Functional Signaling Profiles, which are highly predictive of individual solid tumor response to targeted therapies and combinations, because they are based on the dynamic, predictive signaling information available only from live cells. BioMarker Strategies has been granted patents on both of these important technologies in the United States, Europe, Australia, Canada and Japan, and patent applications are pending elsewhere. (Photo: Business Wire)

“Patents on both of our core technologies have now been granted in the United States, Europe, Australia, Canada and Japan,” said Jerry Parrott, President and CEO, BioMarker Strategies. “These and other granted patents give us broad protection to advance our mission to enable the use of live cells to personalize drug development and treatment selection for patients with solid tumor cancers.”

SnapPath is the only diagnostics system that can generate purified populations of live solid tumor cells from live, unfixed samples in an automated and standardized manner. The system preserves the molecular integrity of these living cells for ex vivo exposure to targeted therapies. This enables the generation of PathMap Functional Signaling Profiles, which are highly predictive of individual solid tumor response to targeted therapies and combinations, because they are based on the dynamic, predictive signaling information available only from live cells.

“The dynamic information available only from live cells is required to understand initial response and the acquired resistance that too often develops in the treatment of cancer,” said Mr. Parrott. “This understanding is necessary for accurate prediction of individual response to targeted treatment of solid tumors.”

Patents Granted BioMarker Strategies for Its SnapPath® Cancer Diagnostics System: “Improved Methods and Devices for Cellular Analysis”

Country/Region	Patent #	Issue Date	Expiration
United States	US9121801	September 1, 2015	December 28, 2030
Europe	EP2210080	January 28, 2015	October 24, 2028
Australia	AU2008317329	January 15, 2015	October 24, 2028
Australia	AU2014277688	January 19, 2017	October 24, 2028
Canada	CA2703631	August 22, 2017	October 24, 2028
Hong Kong	HK1145878	August 14, 2015	October 24, 2028
Japan	JP6177841	July 21, 2017	October 24, 2028
Korea	KR10-1658245	September 9, 2016	October 24, 2028

Patents Granted for the Company’s PathMAP® Functional Signaling Profile Technology: “Compositions for Prediction of Drug Sensitivity, Resistance and Disease Progression”*

Country/Region	Patent #	Issue Date	Expiration
United States	US9766249	September 19, 2017	August 31, 2025
Europe	EP2561368	August 2, 2017	April 18, 2031
Australia	AU2011242990	May 28, 2015	April 18, 2031
Canada	CA2795362	March 20, 2018	April 18, 2031
Japan	JP6158078	June 16, 2017	April 18, 2031
Singapore	SG184507	May 6, 2015	April 18, 2031
*Also officially allowed and proceeding to granted patent in China.

The SnapPath and PathMAP technologies are ideally suited to assess response to targeted drugs in development for the treatment of solid tumor cancers. BioMarker Strategies’ current business development efforts are directed primarily toward providing research services to companies developing targeted drugs and combinations for the treatment of patients with these cancers. The Company expects to enter into its first commercial research services agreements in 2018.

About BioMarker Strategies

BioMarker Strategies is a privately-held molecular diagnostics company founded in 2006 at The Johns Hopkins Science & Technology Park in Baltimore, and now based in Rockville, Maryland. Our mission is to help make personalized medicine more of a reality for patients with solid tumor cancers, by providing powerful new molecular tools and research services to guide targeted drug development and treatment selection. For more information about BioMarker Strategies, please see www.biomarkerstrategies.com.

Forward-Looking Statements

The information in this press release includes our projections and other forward-looking statements regarding future events. In some cases, forward-looking statements may be identified by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “projects,” “estimates,” “predicts,” “potential,” “continue”, etc. These statements are not guarantees of future performance or achievement and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is projected here.